title

OIS Podcast

OIS

0
Followers
0
Plays
OIS Podcast
OIS Podcast

OIS Podcast

OIS

0
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

Welcome to the Ophthalmology Innovation Podcast where you get candid conversations with the leaders & drivers of ophthalmic innovation.

Latest Episodes

J&J’s Tom Frinzi Provides Updates on Innovation Efforts & More

Dr. Ehsan Sadri sits down with industry veteran, Tom Frinzi to learn about Johnson & Johnson’s current innovation efforts, the impact of CMS cutting reimbursement, growth drivers for the premium channel and how they are positioning the company to remain a leader in ophthalmology. Tom also provides some practical career advice.

20 MINSEP 5
Comments
J&J’s Tom Frinzi Provides Updates on Innovation Efforts & More

Mitro Opens Up About Aerie’s Programs

Tom Mitro of Aerie Pharmaceuticals opens up to OIS Podcast host Ehsan Sadri, MD, about the company’s key programs, including the Phase II trial of netarsudil ophthalmic solution for treatment of open-angle glaucoma.

24 MINJUL 11
Comments
Mitro Opens Up About Aerie’s Programs

Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra

Patrick Mooney, head of Novartis’ US eye care business, lays out Novartis’ plans following the spin-out of Alcon and bid to acquire the former Shire ophthalmology franchise from Takeda. Where does Novartis see future growth in eye care? Will ophthalmologists and optometrists see a difference? Is Novartis done acquiring products for a while?

23 MINMAY 15
Comments
Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra

Avedro CEO Reza Zadno Walks Us Through the Recent IPO, Reimbursement Wins, and Future Potential

Avedro Inc. went public on Feb. 14, raising $70 million with its shares pricing at, coincidentally, $14. We talk with Reza Zadno, CEO and president, about the IPO process, which, as you might imagine, she says is as difficult as it looks. We’ll also talk business. Avedro, of course, is a commercial enterprise now, reporting growing sales on its Corneal Crosslinking System that can be used to treat keratoconus, a non-inflammatory eye condition that weakens and misshapes the cornea. What does the future hold for the start-up?

31 MINAPR 25
Comments
Avedro CEO Reza Zadno Walks Us Through the Recent IPO, Reimbursement Wins, and Future Potential

Oculis CEO Riad Sherif Talks About Novartis, Alcon, and What’s Promising in His Company’s Pipeline

Oculis CEO Riad Sherif, who once worked for Novartis and Alcon, reveals which company he’d invest in following the spin-off of the latter from the former – but mostly about the Switzerland-based start-up’s promising new pipeline for DME, post-surgery inflammation, and dry eye.

18 MINAPR 18
Comments
Oculis CEO Riad Sherif Talks About Novartis, Alcon, and What’s Promising in His Company’s Pipeline

Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO

With more than $100 million raised in venture capital and three late-stage clinical programs, Oyster Point Pharma is getting a lot done in a short amount of time. In this podcast, CEO and president Jeffrey Nau reveals how the company is working so quickly and ponders what the next major milestone might be.

31 MINAPR 10
Comments
Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO

Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

After entering the ophthalmology industry “by accident,” Bernhard Günther founded Novaliq in 2004 to pursue therapeutic applications for CyclASol, a novel solution used in drug delivery. While Novaliq pursued other therapeutic applications initially, fate once again brought Günther back into ophthalmology. Today, the company is positioned to deliver two new treatments for dry eye disease. In this podcast we’ll cover the company’s origins, its unusual investor, and its move to the US.

30 MINAPR 2
Comments
Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.

22 MINMAR 21
Comments
What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.

Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

Together, Roche and Biogen paid over $5.5 billion for gene therapy companies Spark and Nightstar. What does this mean for the emerging technology? Spark, of course, received FDA approval for Luxturna as a treatment for inherited retinal disease. But the drug isn’t Roche’s primary focus. Meanwhile, Nightstar’s clinical-stage products could give Biogen a second shot at a gene therapy portfolio after the company severed ties with AGTC in December. Could Biogen make a move to bulk up its ophthalmology offerings?

22 MINMAR 13
Comments
Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

BONUS EPISODE: Direct from OIS@SECO - Industry Leaders Speaking Out on the Optometric Channel

Industry leaders say optometry presents an enormous opportunity for eye care companies.Participants:Joseph Boorady, OD, FAAO, VP, Ocular Surface - Johnson & Johnson VisionRobert Dempsey, Head of Global Ophthalmics Franchise - TakedaDave Gibson, Associate VP, Consumer Eye Care & Customer Development - AllerganAngelo Rago, Global Head, Ophthalmic Diagnostics - Carl Zeiss MeditecCalvin Roberts, MD, SVP, Chief Medical Officer - Bausch + LombModerated By:Emmett T. Cunningham Jr., MD, PhD, MPH, Sr. Managing Director - Blackstone Life Sciences

27 MINFEB 28
Comments
BONUS EPISODE: Direct from OIS@SECO - Industry Leaders Speaking Out on the Optometric Channel

Latest Episodes

J&J’s Tom Frinzi Provides Updates on Innovation Efforts & More

Dr. Ehsan Sadri sits down with industry veteran, Tom Frinzi to learn about Johnson & Johnson’s current innovation efforts, the impact of CMS cutting reimbursement, growth drivers for the premium channel and how they are positioning the company to remain a leader in ophthalmology. Tom also provides some practical career advice.

20 MINSEP 5
Comments
J&J’s Tom Frinzi Provides Updates on Innovation Efforts & More

Mitro Opens Up About Aerie’s Programs

Tom Mitro of Aerie Pharmaceuticals opens up to OIS Podcast host Ehsan Sadri, MD, about the company’s key programs, including the Phase II trial of netarsudil ophthalmic solution for treatment of open-angle glaucoma.

24 MINJUL 11
Comments
Mitro Opens Up About Aerie’s Programs

Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra

Patrick Mooney, head of Novartis’ US eye care business, lays out Novartis’ plans following the spin-out of Alcon and bid to acquire the former Shire ophthalmology franchise from Takeda. Where does Novartis see future growth in eye care? Will ophthalmologists and optometrists see a difference? Is Novartis done acquiring products for a while?

23 MINMAY 15
Comments
Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra

Avedro CEO Reza Zadno Walks Us Through the Recent IPO, Reimbursement Wins, and Future Potential

Avedro Inc. went public on Feb. 14, raising $70 million with its shares pricing at, coincidentally, $14. We talk with Reza Zadno, CEO and president, about the IPO process, which, as you might imagine, she says is as difficult as it looks. We’ll also talk business. Avedro, of course, is a commercial enterprise now, reporting growing sales on its Corneal Crosslinking System that can be used to treat keratoconus, a non-inflammatory eye condition that weakens and misshapes the cornea. What does the future hold for the start-up?

31 MINAPR 25
Comments
Avedro CEO Reza Zadno Walks Us Through the Recent IPO, Reimbursement Wins, and Future Potential

Oculis CEO Riad Sherif Talks About Novartis, Alcon, and What’s Promising in His Company’s Pipeline

Oculis CEO Riad Sherif, who once worked for Novartis and Alcon, reveals which company he’d invest in following the spin-off of the latter from the former – but mostly about the Switzerland-based start-up’s promising new pipeline for DME, post-surgery inflammation, and dry eye.

18 MINAPR 18
Comments
Oculis CEO Riad Sherif Talks About Novartis, Alcon, and What’s Promising in His Company’s Pipeline

Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO

With more than $100 million raised in venture capital and three late-stage clinical programs, Oyster Point Pharma is getting a lot done in a short amount of time. In this podcast, CEO and president Jeffrey Nau reveals how the company is working so quickly and ponders what the next major milestone might be.

31 MINAPR 10
Comments
Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO

Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

After entering the ophthalmology industry “by accident,” Bernhard Günther founded Novaliq in 2004 to pursue therapeutic applications for CyclASol, a novel solution used in drug delivery. While Novaliq pursued other therapeutic applications initially, fate once again brought Günther back into ophthalmology. Today, the company is positioned to deliver two new treatments for dry eye disease. In this podcast we’ll cover the company’s origins, its unusual investor, and its move to the US.

30 MINAPR 2
Comments
Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.

22 MINMAR 21
Comments
What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.

Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

Together, Roche and Biogen paid over $5.5 billion for gene therapy companies Spark and Nightstar. What does this mean for the emerging technology? Spark, of course, received FDA approval for Luxturna as a treatment for inherited retinal disease. But the drug isn’t Roche’s primary focus. Meanwhile, Nightstar’s clinical-stage products could give Biogen a second shot at a gene therapy portfolio after the company severed ties with AGTC in December. Could Biogen make a move to bulk up its ophthalmology offerings?

22 MINMAR 13
Comments
Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

BONUS EPISODE: Direct from OIS@SECO - Industry Leaders Speaking Out on the Optometric Channel

Industry leaders say optometry presents an enormous opportunity for eye care companies.Participants:Joseph Boorady, OD, FAAO, VP, Ocular Surface - Johnson & Johnson VisionRobert Dempsey, Head of Global Ophthalmics Franchise - TakedaDave Gibson, Associate VP, Consumer Eye Care & Customer Development - AllerganAngelo Rago, Global Head, Ophthalmic Diagnostics - Carl Zeiss MeditecCalvin Roberts, MD, SVP, Chief Medical Officer - Bausch + LombModerated By:Emmett T. Cunningham Jr., MD, PhD, MPH, Sr. Managing Director - Blackstone Life Sciences

27 MINFEB 28
Comments
BONUS EPISODE: Direct from OIS@SECO - Industry Leaders Speaking Out on the Optometric Channel
hmly
himalayaプレミアムへようこそ聴き放題のオーディオブックをお楽しみください。